Kristen Massey
Adult Health · Columbia, ILNPI 1003159450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 548 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,577 and has fallen 84.7% since, to $394 in 2025. Among adult health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 548 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- AbbVie$991
- Johnson & Johnson$990
- Pfizer$615
- plus $3K from 30 others
What the payments were for
- Food & beverage$9,134100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 94 | $1,538 |
| AstraZeneca(2 entities) | 45 | $1,032 |
| Novo Nordisk | 61 | $1,031 |
| AbbVie | 72 | $991 |
| Johnson & Johnson | 62 | $990 |
| Pfizer | 46 | $615 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $262 |
| Boehringer Ingelheim | 15 | $250 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $249 |
| Amgen | 11 | $225 |
| Otsuka America Pharmaceutical, Inc. | 11 | $213 |
| Tris Pharma Inc | 14 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $191 |
| Kowa Pharmaceuticals America, Inc. | 15 | $187 |
| Almatica Pharma LLC | 8 | $160 |
| Bayer | 7 | $123 |
| Astellas Pharma US Inc | 4 | $92 |
| E.r. Squibb & Sons, L.L.C. | 5 | $88 |
| Acerus Pharmaceuticals Corporation | 4 | $78 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Novartis | 4 | $68 |
| GSK | 4 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $64 |
| Exact Sciences | 3 | $60 |
| Edwards Lifesciences | 1 | $35 |
| Merck | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Athena Bioscience, LLC | 2 | $27 |
| Argenx US, Inc. | 1 | $26 |
| Neos Therapeutics, LP | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Exeltis, USA Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,149 in reported general payments places this provider in the 95th percentile of 553 adult health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $47,161 |
| JardianceEmpagliflozin | 35 | $26,590 |
| MounjaroTirzepatide | 21 | $21,952 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 134 | $3,545 |
| Celecoxib | 25 | $1,632 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $1,149 |
| Pregabalin | 44 | $1,079 |
| Duloxetine Hcl | 30 | $1,063 |
| Fentanyl | 11 | $965 |
| Ventolin HfaAlbuterol Sulfate | 13 | $927 |
| Tramadol Hcl | 132 | $794 |
| Trazodone Hcl | 27 | $754 |
| Levothyroxine Sodium | 58 | $734 |
| Alprazolam | 167 | $688 |
| Gabapentin | 38 | $599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,031 | $47,16147 claims |
| Boehringer IngelheimJardiance | $250 | $26,59035 claims |
| Lilly USA, LLCMounjaro | $1,538 | $21,95221 claims |
| Almatica Pharma LLCSertraline Hcl | $160 | $18722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 553 adult health providers in Illinois.
Other adult health in Columbia
- Kimberly KearnsHoffman Estates$531K
- Leslie ForresterArlington Heights$97K
- Colleen FolkersChicago$86K
- Matthew BurkeChicago$44K
- Jacklyn GideonChicago$38K
- Jennifer GreenfieldChicago$35K
- Tammy PomaChicago$32K
- Tammy BrownNorth Chicago$31K
- Eileen SchedelAurora$21K
- Julia BuesserGurnee$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.